J Obstet Gynecol Neonatal Nurs. 2024 Sep;53(5):464-476. doi: 10.1016/j.jogn.2024.08.001. Epub 2024 Aug 14.
In July 2023, the U.S. Food and Drug Administration approved Opill (norgestrel 0.075 mg), a progestin-only tablet to prevent pregnancy to be used without a prescription. Although progestin-only birth control pills were approved in 1973, it has taken 50 years for the first oral contraceptive pills to be sold over the counter. In this column, I review the evidence on the barriers to access oral contraceptive pills, the efficacy, preferences and support of a nonprescription progestin-only pill, the cost, and policy implications for health insurance coverage. I conclude with recommendations from professional organizations on over-the-counter access to hormonal contraception.
2023 年 7 月，美国食品和药物管理局批准了无需处方即可使用的孕激素-only 片剂 Opill（去氧孕烯 0.075 毫克）来避孕。虽然孕激素-only 避孕药于 1973 年获得批准，但第一种口服避孕药在 50 年后才开始在柜台出售。在这篇专栏文章中，我回顾了关于口服避孕药获取障碍、非处方孕激素-only 药丸的疗效、偏好和支持、成本以及对健康保险覆盖范围的政策影响的证据。最后，我根据专业组织的建议，对激素避孕的非处方获取提出了建议。
